Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | TLR4 | O00206 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | MT-CO2 | P00403 | 2/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11820023 | 0.86 | TRPV1 (0.43) | ALDH1A1L3MBTL1KDM4ETLR4MT-CO2 | |
| SCHEMBL3325889 | 0.84 | PLOD2 (0.43) | ALDH1A1MAPTL3MBTL1KDM4ENPC1 | |
| SCHEMBL2993114 | 0.83 | ALDH1A1 (0.49) | ALDH1A1MAPTL3MBTL1KDM4ENPC1 | |
| SCHEMBL11815188 | 0.82 | ALDH1A1 (0.48) | ALDH1A1MAPTL3MBTL1KDM4ENPC1 | |
| SCHEMBL3322059 | 0.81 | MT-CO2 (0.43) | ALDH1A1MAPTL3MBTL1TLR4MT-CO2 | |
| SCHEMBL11838776 | 0.78 | KDM4E (0.66) | ALDH1A1MAPTL3MBTL1KDM4ENPC1 | |
| SCHEMBL11815406 | 0.78 | CHRNA7 (0.51) | ALDH1A1MAPTL3MBTL1KDM4ELMNA | |
| SCHEMBL3327919 | 0.77 | KDM4E (0.73) | ALDH1A1MAPTL3MBTL1KDM4ENPC1 | |
| SCHEMBL3320253 | 0.76 | TLR4 (0.56) | TLR4MT-CO2ALOX5 | |
| SCHEMBL11836745 | 0.76 | KDM4E (0.71) | ALDH1A1MAPTL3MBTL1KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2813498-B1 | Compounds for Alzheimer's disease | MANFREDI JOHN (US) | 2016-04-20 | — | — | EP | disclosed |
| EP-2139472-B1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2016-01-13 | — | — | EP | disclosed |
| EP-2139472-B1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2016-01-13 | — | — | EP | disclosed |
| US-9216966-B2 | Compounds for Alzheimer's disease | Manfredi, John (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216966-B2 | Compounds for Alzheimer's disease | Manfredi, John (US) | 2015-12-22 | — | — | US | disclosed |
| US-9034871-B2 | Compounds for Alzheimer's disease | Manfredi, John (US) | 2015-05-19 | — | — | US | disclosed |
| US-9034871-B2 | Compounds for Alzheimer's disease | Manfredi, John (US) | 2015-05-19 | — | — | US | disclosed |
| EP-2813498-A1 | Compounds for Alzheimer's disease | Manfredi, John (US) | 2014-12-17 | — | — | EP | disclosed |
| WO-2014164222-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | MANFREDI JOHN (US) | 2014-10-09 | — | — | WO | disclosed |
| EP-1809601-B1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | MANFREDI JOHN (US) | 2014-09-10 | — | — | EP | disclosed |
| US-20090099179-A1 | COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INCORPORATED (US) | 2009-04-16 | — | — | US | disclosed |
| EP-2000176-A1 | Tetrahydroindole derivatives as NADPH Oxidase inhibitors | GenKyo Tex (CH) | 2008-12-10 | — | — | EP | disclosed |
| EP-2000176-A1 | Tetrahydroindole derivatives as NADPH Oxidase inhibitors | GenKyo Tex (CH) | 2008-12-10 | — | — | EP | disclosed |
| US-20080249135-A1 | N-phenylindoles; oral dosage forms; side effect reduction | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249135-A1 | N-phenylindoles; oral dosage forms; side effect reduction | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
| WO-2008116926-A1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYO TEX SA (CH) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116926-A1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYO TEX SA (CH) | 2008-10-02 | — | — | WO | disclosed |
| WO-2007115306-A2 | COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| US-3997557-A | ANTIARRHYTHMIA, CNS DEPRESSANT, ANTIINFLAMMATORY, HYPOTENSIVE | AMERICAN HOECHST CORPORATION (US) | 1976-12-14 | — | — | US | disclosed |
| US-3931407-A | ANTIINFLAMMATORY, ANALGESIC | AMERICAN HOECHST CORPORATION (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099179-A1 | COMPOUNDS FOR DISEASES AND DISORDERS | CLN6, NLN, CLTC | ALDH1A1 1938/4885MAPT 657/4885L3MBTL1 191/4885 |
| US-20080249135-A1 | N-phenylindoles; oral dosage forms; side effect reduction | NCL, PSEN2, CCNO | ALDH1A1 2795/4885MAPT 46/4885L3MBTL1 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.